Eli Lilly

News

AZ backs diabetes drug Farxiga with new cardio analysis

AstraZeneca continues to make the case for its Farxiga diabetes drug, highlighting a cardiology analysis that it hopes will convince more doctors to prescribe it in a highly competitive mar

Views & Analysis

R&D round-up: Non-opioid painkiller space heats up

As the MHRA announced that it would be convening an Expert Working

News

Lilly's Cyramza hits mark in first-line lung cancer trial

Eli Lilly has produced phase 3 data that supports use of its Cyramza combined with Roche's Tarceva in first-line non-small cell lung cancer with EGFR mutations, paving the way for filings w

News

More positive results for Pfizer/Lilly’s non-opioid pain dru...

Pfizer and Eli Lilly have announced more positive results from a phase 3 study of their non-opioid pain drug tanezumab, this time in chronic lower back pain (CBLP).

News

Novartis and Lilly CEOs back Trump plans to cut drug prices

CEOs from Novartis and Eli Lilly have backed US government proposals to cut out “middlemen” in the health system, who have inflated the costs of their medicines.

News

Lilly scores with two Olumiant trials in atopic dermatitis

Eli Lilly has two positive trials of its JAK inhibitor Olumiant in skin disorder atopic dermatitis (AD), which could finally unlock the drug’s potential in the US.

AZ backs diabetes drug Farxiga with new cardio analysis

R&D round-up: Non-opioid painkiller space heats up

Lilly's Cyramza hits mark in first-line lung cancer trial

More positive results for Pfizer/Lilly’s non-opioid pain dru...

Novartis and Lilly CEOs back Trump plans to cut drug prices

Lilly scores with two Olumiant trials in atopic dermatitis

Biotech is back, with Craig Ackerman

Using AI-driven synthetic personas to take your insights fur...

Eli Lilly

Editor's Picks